Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer

Abstract

High microvessel density, an indirect measure of angiogenesis, has been shown to correlate with increased tumour size, lymph node involvement and poor prognosis in non-small-cell lung cancer (NSCLC). Tumour cell vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PD-ECGF) expression correlate with angiogenesis and a poor outcome in this disease. In a retrospective study VEGF and PD-ECGF expression and microvessel density were evaluated immunohistochemically in surgically resected specimens (T1-3, N0-2) from 223 patients with operable NSCLC using the VG1, P-GF.44C and JC70 monoclonal antibodies respectively. High VEGF immunoreactivity was seen in 104 (46.6%) and PD-ECGF in 72 (32.3%) cases and both were associated with high vascular grade tumours (P= 0.009 and P= 0.05 respectively). Linear regression analysis revealed a weak positive correlation between VEGF and PD-ECGF expression in cancer cells (r= 0.21; P = 0.002). Co-expression of VEGF and PD-ECGF was not associated with a higher microvessel density than VEGF or PD-ECGF only expressing tumours. Furthermore a proportion of high vascular grade tumours expressed neither growth factor. Univariate analysis revealed tumour size, nodal status, microvessel density and VEGF and PD-ECGF expression as significant prognostic factors. Tumour size (P < 0.02) and microvessel density (P < 0.04) remained significant on multivariate analysis. In conclusion, VEGF and PD-ECGF are important angiogenic growth factors and have prognostic significance in NSCLC. Furthermore the study underlines the prognostic significance of microvessel density in operable NSCLC.

References 38

1. 1.

   Amaya H., Tanigawa N., Lu C., Matsumura M., Shimomatsuya T., Horiuchi T., Muraoka R. Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer. Cancer Lett. 1997;119(2):227-235.

   Not in our library10.1016/s0304-3835(97)00280-2

2. 2.

   Apolinario R. M., van der Valk P., de Jong J. S., Deville W., van Ark-Otte J., Dingemans A. M., van Mourik J. C., Postmus P. E., Pinedo H. M., Giaccone G. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol. 1997;15(6):2456-2466.

   Not in our library10.1200/jco.1997.15.6.2456

3. 3.

   Arenberg D. A., Polverini P. J., Kunkel S. L., Shanafelt A., Hesselgesser J., Horuk R., Strieter R. M. The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer. J Leukoc Biol. 1997;62(5):554-562.

   Not in our library10.1002/jlb.62.5.554

4. 4.

   Budman D. R., Meropol N. J., Reigner B., Creaven P. J., Lichtman S. M., Berghorn E., Behr J., Gordon R. J., Osterwalder B., Griffin T. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol. 1998;16(5):1795-1802.

   Not in our library10.1200/jco.1998.16.5.1795

5. 5.

   Chandrachud L. M., Pendleton N., Chisholm D. M., Horan M. A., Schor A. M. Relationship between vascularity, age and survival in non-small-cell lung cancer. Br J Cancer. 1997;76(10):1367-1375.

   Not in our library10.1038/bjc.1997.562

6. 6.

   Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18(1):4-25.

   Not in our library10.1210/edrv.18.1.0287

7. 7.

   Fontanini G., Boldrini L., Chinè S., Pisaturo F., Basolo F., Calcinai A., Lucchi M., Mussi A., Angeletti C. A., Bevilacqua G. Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas. Br J Cancer. 1999;79(2):363-369.

   Not in our library10.1038/sj.bjc.6690058

8. 8.

   Fontanini G., Lucchi M., Vignati S., Mussi A., Ciardiello F., De Laurentiis M., De Placido S., Basolo F., Angeletti C. A., Bevilacqua G. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst. 1997;89(12):881-886.

   Not in our library10.1093/jnci/89.12.881

9. 9.

   Fox S. B., Engels K., Comley M., Whitehouse R. M., Turley H., Gatter K. C., Harris A. L. Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF. Ann Oncol. 1997;8(3):271-275.

   Not in our library10.1023/a:1008280110558

10. 10.

    Fox S. B., Leek R. D., Weekes M. P., Whitehouse R. M., Gatter K. C., Harris A. L. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol. 1995;177(3):275-283.

    Not in our library10.1002/path.1711770310

11. 11.

    Giatromanolaki A., Koukourakis M. I., Comley M., Kaklamanis L., Turley H., O'Byrne K., Harris A. L., Gatter K. C. Platelet-derived endothelial cell growth factor (thymidine phosphorylase) expression in lung cancer. J Pathol. 1997;181(2):196-199.

    Not in our library10.1002/(sici)1096-9896(199702)181:2<196::aid-path763>3.0.co;2-u

12. 12.

    Giatromanolaki A., Koukourakis M. I., Kakolyris S., Turley H., O'Byrne K., Scott P. A., Pezzella F., Georgoulias V., Harris A. L., Gatter K. C. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res. 1998;4(12):3017-3024.

    Not in our library

13. 13.

    Giatromanolaki A., Koukourakis M., O'Byrne K., Fox S., Whitehouse R., Talbot D. C., Harris A. L., Gatter K. C. Prognostic value of angiogenesis in operable non-small cell lung cancer. J Pathol. 1996;179(1):80-88.

    Not in our library10.1002/(sici)1096-9896(199605)179:1<80::aid-path547>3.0.co;2-x

14. 14.

    Harris A. L. Are angiostatin and endostatin cures for cancer? Lancet. 1998;351(9116):1598-1599.

    Not in our library10.1016/s0140-6736(98)22022-8

15. 15.

    Igarashi M., Dhar D. K., Kubota H., Yamamoto A., El-Assal O., Nagasue N. The prognostic significance of microvessel density and thymidine phosphorylase expression in squamous cell carcinoma of the esophagus. Cancer. 1998;82(7):1225-1232.

    Not in our library10.1002/(sici)1097-0142(19980401)82:7<1225::aid-cncr3>3.0.co;2-e

16. 16.
    Prognostic significance of angiogenesis in human pancreatic cancer · 1999

    No notice
17. 17.

    Ishikawa F., Miyazono K., Hellman U., Drexler H., Wernstedt C., Hagiwara K., Usuki K., Takaku F., Risau W., Heldin C. H. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature. 1989;338(6216):557-562.

    Not in our library10.1038/338557a0

18. 18.

    Jäger R., Noll K., Havemann K., Pflüger K. H., Knabbe C., Rauvala H., Zugmaier G. Differential expression and biological activity of the heparin-binding growth-associated molecule (HB-GAM) in lung cancer cell lines. Int J Cancer. 1997;73(4):537-543.

    Not in our library10.1002/(sici)1097-0215(19971114)73:4<537::aid-ijc14>3.0.co;2-6

19. 19.

    Kim K. J., Li B., Winer J., Armanini M., Gillett N., Phillips H. S., Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362(6423):841-844.

    Not in our library10.1038/362841a0

20. 20.

    Koomägi R., Volm M. Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis. Int J Cancer. 1998;79(1):19-22.

    Not in our library10.1002/(sici)1097-0215(19980220)79:1<19::aid-ijc4>3.0.co;2-z

21. 21.

    Koukourakis M. I., Giatromanolaki A., Kakolyris S., O'Byrne K. J., Apostolikas N., Skarlatos J., Gatter K. C., Harris A. L. Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: impact on tumour neoangiogenesis and survival. Br J Cancer. 1998;77(10):1696-1703.

    Not in our library10.1038/bjc.1998.280

22. 22.

    Lin P., Sankar S., Shan S., Dewhirst M. W., Polverini P. J., Quinn T. Q., Peters K. G. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ. 1998;9(1):49-58.

    Not in our library

23. 23.

    Macaulay V. M., O'Byrne K. J., Saunders M. P., Braybrooke J. P., Long L., Gleeson F., Mason C. S., Harris A. L., Brown P., Talbot D. C. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res. 1999;5(3):513-520.

    Not in our library

24. 24.

    Maeda K., Kang S. M., Ogawa M., Onoda N., Sawada T., Nakata B., Kato Y., Chung Y. S., Sowa M. Combined analysis of vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression in gastric carcinoma. Int J Cancer. 1997;74(5):545-550.

    Not in our library10.1002/(sici)1097-0215(19971021)74:5<545::aid-ijc12>3.0.co;2-5

25. 25.

    Moghaddam A., Bicknell R. Expression of platelet-derived endothelial cell growth factor in Escherichia coli and confirmation of its thymidine phosphorylase activity. Biochemistry. 1992;31(48):12141-12146.

    Not in our library10.1021/bi00163a024

26. 26.

    Moghaddam A., Zhang H. T., Fan T. P., Hu D. E., Lees V. C., Turley H., Fox S. B., Gatter K. C., Harris A. L., Bicknell R. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci U S A. 1995;92(4):998-1002.

    Not in our library10.1073/pnas.92.4.998

27. 27.

    Oshika Y., Nakamura M., Tokunaga T., Ozeki Y., Fukushima Y., Hatanaka H., Abe Y., Yamazaki H., Kijima H., Tamaoki N. Expression of cell-associated isoform of vascular endothelial growth factor 189 and its prognostic relevance in non-small cell lung cancer. Int J Oncol. 1998;12(3):541-544.

    Not in our library10.3892/ijo.12.3.541

28. 28.

    Patterson A. V., Zhang H., Moghaddam A., Bicknell R., Talbot D. C., Stratford I. J., Harris A. L. Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br J Cancer. 1995;72(3):669-675.

    Not in our library10.1038/bjc.1995.392

29. 29.

    Pezzella F., Pastorino U., Tagliabue E., Andreola S., Sozzi G., Gasparini G., Menard S., Gatter K. C., Harris A. L., Fox S. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol. 1997;151(5):1417-1423.

    Not in our library

30. 30.

    Schor A. M., Pazouki S., Morris J., Smither R. L., Chandrachud L. M., Pendleton N. Heterogeneity in microvascular density in lung tumours: comparison with normal bronchus. Br J Cancer. 1998;77(6):946-951.

    Not in our library10.1038/bjc.1998.156

31. 31.

    Skobe M., Rockwell P., Goldstein N., Vosseler S., Fusenig N. E. Halting angiogenesis suppresses carcinoma cell invasion. Nat Med. 1997;3(11):1222-1227.

    Not in our library10.1038/nm1197-1222

32. 32.

    Takahashi Y., Bucana C. D., Akagi Y., Liu W., Cleary K. R., Mai M., Ellis L. M. Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer. Clin Cancer Res. 1998;4(2):429-434.

    Not in our library

33. 33.

    Takebayashi Y., Akiyama S., Akiba S., Yamada K., Miyadera K., Sumizawa T., Yamada Y., Murata F., Aikou T. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst. 1996;88(16):1110-1117.

    Not in our library10.1093/jnci/88.16.1110

34. 34.

    Toi M., Inada K., Hoshina S., Suzuki H., Kondo S., Tominaga T. Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer. Clin Cancer Res. 1995;1(9):961-964.

    Not in our library

35. 35.

    Turley H., Scott P. A., Watts V. M., Bicknell R., Harris A. L., Gatter K. C. Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1. J Pathol. 1998;186(3):313-318.

    Not in our library10.1002/(sici)1096-9896(1998110)186:3<313::aid-path188>3.0.co;2-x

36. 36.

    Volm M., Koomägi R., Mattern J. Interrelationships between microvessel density, expression of VEGF and resistance to doxorubicin of non-small lung cell carcinoma. Anticancer Res. 1996;16(1):213-217.

    Not in our library

37. 37.

    Whittle C., Gillespie K., Harrison R., Mathieson P. W., Harper S. J. Heterogeneous vascular endothelial growth factor (VEGF) isoform mRNA and receptor mRNA expression in human glomeruli, and the identification of VEGF148 mRNA, a novel truncated splice variant. Clin Sci (Lond). 1999;97(3):303-312.

    Not in our library

38. 38.

    van Zandwijk N., Giaccone G. Treatment of metastatic non-small cell lung cancer. Curr Opin Oncol. 1996;8(2):120-125.

    Not in our library10.1097/00001622-199603000-00008

Cited by papers we hold 3

• The Platelet Response to Tissue Injury · 2018
  No notice
• Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis · 2003
  No notice
• The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis · 2002
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.